Advanced searches left 3/3

Protocol - ClinicalTrials.gov

Summarized by Plex Scholar
Last Updated: 24 September 2022

* If you want to update the article please login/register

NIAAA Natural History Protocol

Study Summary: This paper represents the preliminary results of the NIAAA's natural history program with the main aim of achieving deep phenotyping of patients across the alcohol use spectrum. Patients with Alcohol Use Disorders, patients with severe alcohol intake, social drinking, and patients with Abstinent are among Alcohol Use Disorders patients, physicians with a problem drinking pattern, and patients with Abstinent are among those affected by Alcohol use disorders. In all patients, a standard set of records will be collected, allowing us to investigate the effects of alcohol use in their overall health. Any individual over the age of 18 years or other research studies conducted at NIAAA during the brief telephone pre-screening can be accepted. Participants may include people with no current or past AUD, as well as individuals with current or past DSM requirements for AUD. Participants will be either admitted to the NIAAA 1SE unit for inpatient care or seen in the NIAAA Outpatient Alcohol Clinic. Participant Duration: 30 years Participant Duration: 30 years Participant Duration: This year's 30 years participant in the study's 30 years; Treatment-seeking patients will also be given an outpatient follow-up for up to three months after being released from the hospital hospital. If that is the case, a new series of data to track progression of the disease will be obtained. In the case that these people call calling for AUD therapy, they will return to a new set of data, and a new set of data may be collected. Patients will be considered active for up to one year after they sign up.

Source link: https://clinicaltrials.gov/ct2/show/NCT02231840


Vascular Disease Discovery Protocol

The NIH gives research scientists the opportunity to participate in the bench-to-bedside process, which is essential for the full implementation of translational medicine programs. Large patient populations provide the opportunity to find rare genetic variants responsible for human disease that could have ramifications for human health. We'll also investigate rare genetic modifiers and identify novel disease causes of common vascular diseases. This protocol, in addition to its role in evaluating individuals who are of concern to the NHL Translational Vascular Medicine Branch of the NHLBI, the Center for Applied Vascular Medicine (NIH), or other NIH protocols where vascular phenotypes exist, provides a potential route for admitting participants from other NIH studies, such as the NIH Undiagnosed Diseases Program, the Center for Human Immunology Trans-Institute program, or other NIH studies in which demonstrate vascular NIH Protocol.

Source link: https://clinicaltrials.gov/ct2/show/NCT03538639


Cardiovascular Disease Discovery Protocol

We will also look at rare genetic modifiers and identify novel disease causes of common cardiovascular diseases. Individuals who participate in this protocol may lead to the establishment of specific disease-related protocols involving extensive natural history research, disease discovery, and potential experimental therapeutic studies. This protocol, in addition to its role in monitoring individuals of concern to the NHL Cardiovascular Branch, the Center for Human Immunology Trans-Institute program, or other NIH studies where cardiovascular characteristics are present, provides a potential route for admitting subjects from other NIH programs, such as the NIH Undiagnosed Diseases Program, the Centre for Human Immunology Trans-Institute Program, or other NIH protocols where cardiovascular characteristics are present.

Source link: https://clinicaltrials.gov/ct2/show/NCT01143454


Screening Protocol for Patients With Stroke

Objectives: The aim of this research is to determine stroke patients for the studies looking at the causal causes of brain lesions like stroke, and physical therapy to improve motor recovery.

Source link: https://clinicaltrials.gov/ct2/show/NCT01021033


Teaching Protocol for the Evaluation of Plasma Lipoproteins

Changes in both the stable state concentrations of the various lipoproteins and in the metabolism of these particles are caused by Inborn errors in the lipoprotein transport system. Profound changes in the ambient lipoprotein concentrations of Profound have a variety of clinical manifestations. The protocol would also include education of students, staff clinicians, physician assistants, nurse practitioners, and post-doctoral fellows in the assessment and treatment of patients with dyslipidemias. Patients with dyslipidemia, triglycerides, HDL-cholesterol, or the NHL Lipid website may have an elevated plasma level of cholesterol, triglycerides, HDL-cholesterol, or corneal opacities.

Source link: https://clinicaltrials.gov/ct2/show/NCT00001168


Orphan Europe Carbaglu® Surveillance Protocol

The rarest of the urea cycle disorders is N-acetylglutamate synthase deficiency. The United States Food and Drug Administration recommended carglumic acid as an adjunctive therapy for acute hyperammonemia due to the deficiency of the hepatic enzyme NAGS and as a maintenance therapy for chronic hyperammonemia due to NAGS deficiency. " "Agency can be identified as a result of NAGS deficiency. '" As post-marketing regulations arise, ORphanage for chronic hyperammonemia due to NAGS deficiency, as an a 1604-3: A review of the effects of carglumic acid on pregnancy and fetal outcomes. The Urea Cycle Disorders Consortium's longitudinal Study of Urea Cycle Disorders in the United States will lead to increased patient registry or monitoring protocols. In the United States, it also intends to gather data on all patients with NAGS deficiency.

Source link: https://clinicaltrials.gov/ct2/show/NCT03409003


Screening Protocol for Genetic Diseases of Allergic Inflammation

The results of research lab testing findings may be used to compare clinical experience to study lab testing findings. Outside medical records can be obtained for chart review or chart analysis to compare clinical history to research laboratory findings. Patients will be referred to other appropriate NIH protocols for additional clinical investigation and treatment, where appropriate. Up to 1000 people and family members can be included in the study.

Source link: https://clinicaltrials.gov/ct2/show/NCT00852943

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions